MS Stat2 Clinical Trial
31 July 2018
MS-Stat2 Clinical Drug Trial
The Anne Rowling Clinic is part of a major phase III trial to test whether simvastatin could become a treatment for progressive MS.
It is hoped that this phase III double blind randomised placebo-controlled trial will establish definitively whether simvastatin is able to slow the rate of progression over a three year period, with the trial starting at the Anne Rowling Clinic on 1st August 2018.
The trial will test simvastatin, a cheap cholesterol lowering drug, in people with the secondary progressive form of MS. A phase II trial of 140 people with secondary progressive MS into simvastatin at UCL, Institute of Neurology led by Dr Jeremey Chataway, found that those taking high doese of the drug had a significant reduction in the rate of brain atrophy (brain shrinkage) over two years and also had better disability scores at the end of the study.
If you have a diagnosis of secondary progressive MS, are aged between 25 & 65 years and have an EDSS of between 4.00 & 6.5 (inclusive) and are able to attend the Anne Rowling Clinic for repeat visits, you can register your interest to participate in this study (exclusion criteria will apply to this study), then please register your name at Rowling-CARE. Alternatively you can call and speak to Dawn Lyle, MS Stat 2 lead research nurse on 0131 465 9512.